Abstract: TH-PO1079
Management of Uncontrolled Gout Among Nephrology Professionals: Findings from a Medical Chart Audit
Session Information
- CKD: Epidemiology, Risk Factors, and Other Conditions
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Desai, Bhavisha, Sobi Inc, Waltham, Massachusetts, United States
- Choi, Hyon, Massachusetts General Hospital, Boston, Massachusetts, United States
- Kragh, Nana, Swedish Orphan Biovitrum AB publ, Stockholm, Sweden
- Athavale, Amod, Trinity Partners LLC, Waltham, Massachusetts, United States
- Gulaid, Amal, Trinity Partners LLC, Waltham, Massachusetts, United States
- Oladapo, Abiola, Sobi Inc, Waltham, Massachusetts, United States
- Smith, Brittany, Trinity Partners LLC, Waltham, Massachusetts, United States
- Saag, Kenneth G., University of Alabama at Birmingham Health System, Birmingham, Alabama, United States
Background
Uncontrolled gout (UG) is a persistent form of gout with active symptoms (gout flares, tophi, etc.) and high serum uric acid (sUA) levels (>6 mg/dL) despite use of oral urate lowering therapies (ULT). Patients with chronic kidney disease (CKD) have a 5x higher prevalence of gout than those without. This study assesses current management and clinical presentation of UG in patients with CKD managed by nephrologists in the United States (US).
Methods
US board-certified nephrologists, with ≥3 years of clinical practice and ≥25 patients with gout (≥5 with UG) managed over the last year participated in a retrospective, web-enabled chart audit study from March-June 2024. Physicians provided perceptions of UG management and abstracted data from eligible patient charts: diagnosed with UG, had gout-related symptoms over the last year and sUA>6 mg/dL.
Results
Seventy-five nephrologists abstracted 202 charts of patients with UG. Most patients (97%) had diagnosed CKD of which 31% were Stage 3b. Mean (SD) age of patients at gout diagnosis was 49 (11) years. Besides CKD, common comorbidities were hypertension (48%), obesity (35%) and diabetes (32%). At most recent visit, the mean (SD) sUA was 8.2 mg/dL (0.8), with patients experiencing visible tophi (87%), joint pain (43%), swollen joints (42%) and gout flares (32%). ULTs most recently administered were allopurinol (60%), febuxostat (35%), colchicine (18%) and pegloticase (7%). About 37% of patients were considered adherent (i.e., taking medication >75% of the time) with lack of compliance most attributed to forgetfulness (58%). In the past year, 27% of patients had gout-related emergency room visits and 5% were hospitalized for a mean (SD) of 2 (1) days. Most nephrologists (96%) believed patients were impacted by the burden of current gout treatments and UG at least moderately impacted patients’ overall quality of life (98%), hobbies (90%), social life (85%-88%) and family life (83%). Furthermore, 93% expressed a need for treatments for UG patients with CKD.
Conclusion
Despite available ULTs, patients with UG and CKD still have high sUA levels and experience gout-related symptoms which negatively impact their quality of life. These findings highlight the existing burden in patients with UG and CKD as well as a need for treatment optimization and new therapies.
Funding
- Commercial Support – Sobi Inc. provided funding for this study